Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 2;6(243):243fs26.
doi: 10.1126/scitranslmed.3009586.

Functional genomics for personalized cancer therapy

Jeffrey W Tyner  1
Affiliations

Functional genomics for personalized cancer therapy

Jeffrey W Tyner. Sci Transl Med. .

Abstract

Integration of functional and genomic screening strategies reveals clinically actionable genetic events that impact the effectiveness of cancer treatment regimens and the outcomes of cancer patients.

PubMed Disclaimer

Conflict of interest statement

I have received research funding from Incyte Pharmaceuticals. A patent is pending on the use of CSF3R mutation as a diagnostic tool in hematologic malignancies.

Figures

Fig. 1
Fig. 1. Functional genomics approach: current and future
To comprehensively define the functional genomic landscape of cancer, we are currently performing parallel analyses of primary specimens from patients with hematologic malignancies. Genomic analysis reveals a large number of genetic events, most of which are seen in very small fractions of patients. Functional screening shows heterogeneous patterns of drug sensitivity with unclear genetic etiology. By integrating these data streams, we have identified pathogenetically important and clinically actionable genetic events, such as dependence on ROR1 and the pre–B cell receptor in t(1;19)-ALL and mutant CSF3R signaling in CNL. As we learn more from this platform, we build toward a future in which personalized, targeted therapies are prescribed solely on the basis of rapid genomic analysis of individual patient tumor specimens.
See this image and copyright information in PMC

References

    1. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O’Hare T, Heinrich MC, Druker BJ. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA. 2009;106:8695–8700. - PMC - PubMed
    1. Tyner JW, Yang WF, Bankhead A, 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O’Hare T, Druker BJ, Loriaux MM. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2013;73:285–296. - PMC - PubMed
    1. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012;22:656–667. - PMC - PubMed
    1. Glover JM, Loriaux M, Tyner JW, Druker BJ, Chang BH. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;59:576–579. - PMC - PubMed
    1. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010;116:4532–4541. - PMC - PubMed

Publication types

LinkOut - more resources